The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Gilead Sciences Submits NDA for Ledipasvir/Sofosbuvir Combination for Genotype 1 Chronic Hepatitis C
September 25, 2014
- AnGes MG to Start Collategene Administration in PIII Study in US as Early as October
September 25, 2014
- Ibandronate Oral Agent to Be Filed for Japan Approval in 2015: Chugai, Taisho
September 24, 2014
- Meiji Seika Pharma Seeks New Indication for Laserphyrin
September 24, 2014
- Mediceo Sets to Increase Qualified Reps to 2,000, Enter Contract PMS Biz within 3 Years
September 22, 2014
- Bristol-Myers Submits NDA for Malignant Melanoma Drug Ipilimumab
September 22, 2014
- Additional Indication Approved for MTPC’s Telavic
September 22, 2014
- RaQualia Wins Use-Patent Allowance for EP4 Antagonist in US
September 22, 2014
- Bayer’s Japan Open Innovation Center Now Up and Running
September 22, 2014
- Sadao Furuichi to Double as Heads of Kracie Pharma, Kracie Pharmaceutical
September 22, 2014
- Huya Bioscience International Opens Tokyo Office
September 19, 2014
- MTPC Generic Arm Seeks to Quickly Broaden Product Lineup, New Alliance a Possibility: Pres.
September 18, 2014
- Takeda to Reshuffle Global Structure in April
September 18, 2014
- Toray Partners with German Firm on Sales of Hemoperfusion Device in Europe
September 18, 2014
- Allergan, Shionogi Tie Up for Sales of Eyelash Hypotrichosis Agent
September 18, 2014
- Bayer Paid 10.1 Billion Yen to Healthcare Professionals in 2013
September 18, 2014
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
- Eli Lilly, AstraZeneca to Codevelop BACE Inhibitor for AD Treatment
September 18, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…